These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 22688250)
1. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. Minocha M; Khurana V; Qin B; Pal D; Mitra AK Int J Pharm; 2012 Oct; 436(1-2):127-34. PubMed ID: 22688250 [TBL] [Abstract][Full Text] [Related]
2. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. Minocha M; Khurana V; Qin B; Pal D; Mitra AK Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931 [TBL] [Abstract][Full Text] [Related]
3. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. de Vries NA; Buckle T; Zhao J; Beijnen JH; Schellens JH; van Tellingen O Invest New Drugs; 2012 Apr; 30(2):443-9. PubMed ID: 20963470 [TBL] [Abstract][Full Text] [Related]
4. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475 [TBL] [Abstract][Full Text] [Related]
5. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Lagas JS; van Waterschoot RA; van Tilburg VA; Hillebrand MJ; Lankheet N; Rosing H; Beijnen JH; Schinkel AH Clin Cancer Res; 2009 Apr; 15(7):2344-51. PubMed ID: 19276246 [TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323 [TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210 [TBL] [Abstract][Full Text] [Related]
8. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535 [TBL] [Abstract][Full Text] [Related]
9. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. Bihorel S; Camenisch G; Lemaire M; Scherrmann JM J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [ Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684 [TBL] [Abstract][Full Text] [Related]
11. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331 [TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160 [TBL] [Abstract][Full Text] [Related]
13. Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates. Tournier N; Goutal S; Auvity S; Traxl A; Mairinger S; Wanek T; Helal OB; Buvat I; Soussan M; Caillé F; Langer O J Nucl Med; 2017 Jan; 58(1):117-122. PubMed ID: 27493269 [TBL] [Abstract][Full Text] [Related]
14. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier. Wang T; Agarwal S; Elmquist WF J Pharmacol Exp Ther; 2012 May; 341(2):386-95. PubMed ID: 22323823 [TBL] [Abstract][Full Text] [Related]
15. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier. Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927 [TBL] [Abstract][Full Text] [Related]
16. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Bihorel S; Camenisch G; Lemaire M; Scherrmann JM Pharm Res; 2007 Sep; 24(9):1720-8. PubMed ID: 17380257 [TBL] [Abstract][Full Text] [Related]
17. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087 [TBL] [Abstract][Full Text] [Related]
18. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system. Sane R; Agarwal S; Mittapalli RK; Elmquist WF J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054 [TBL] [Abstract][Full Text] [Related]
19. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939 [TBL] [Abstract][Full Text] [Related]
20. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]